Dr Leung is the founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited. Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited.
Dr Leung has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist who successfully developed humanised anti-CD22 antibody and introduced the concept of “Functional Humanisation”. Dr Leung currently also serves as an Adjunct Professor at The Hong Kong University of Science and Technology. He held positions as the Executive Director of a leading US antibody-drug conjugate company as well as the Managing Director of The Hong Kong Institute of Biotechnology Limited.
Dr Leung obtained his BSc and MPhil in biochemistry, as well as EMBA from CUHK. He earned his DPhil in molecular biology from the University of Oxford in the UK in May 1989. He was also a postdoctoral fellow at Yale University in the US from July 1989 to June 1991.